Hodgkin Lymphoma

Show Only Open Trials
1.

Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb Research & Development
  • Disease Status and/or Stage: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphomas
  • Protocol ID: WCMC IRB #1404015005; Sponsor Protocol #CA224022
2.

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: classical Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1406015182; Sponsor Protocol #CA209-205; ClinicalTrials.gov #NCT02181738
3.

A Pilot Study to Evaluate Immunologic Biomarkers of Treatment Response and Disease Activity in Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: New York University Cancer Institute
  • Disease Status and/or Stage: Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1305013885; Sponsor Protocol #S12-02437
4.

Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Advanced classical hodgkin lymphoma
  • Protocol ID: WCMC IRB Protocol #1308014217; Sponsor Protocol # C25003; ClinicalTrials.gov #NCT01712490
5.

A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
6.

A phase II study of brentuximab vedotin as salvage therapy for Hodgkin Lymphoma prior to autologous hematopoietic stem cell transplantation

  • Study Status: Open to Enrollment
  • Sponsor: City of Hope
  • Disease Status and/or Stage: Relapsed or Refractory to One Frontline Induction Therapy
7.

A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
8.

A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
9.

BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

  • Study Status: Open to Enrollment
  • Sponsor: BMT-CTN
  • Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
  • Protocol ID: BMT CTN 0903
10.

CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission of Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Bulky, Early Stage Hodgkin Lymphoma
11.

CALGB 50604: Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

  • Study Status: Closed to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Hodgkin Lymphoma, Stage IA, IB, IIA or IIB
  • Protocol ID: CALGB 50604
12.

Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated Hodgkin Lymphoma

Top of page